生物
蛋白质基因组学
阿波贝克
肺癌
疾病
腺癌
蛋白质组学
癌症研究
癌症
基因
遗传学
肿瘤科
计算生物学
生物信息学
基因组学
病理
基因组
医学
作者
Yi‐Ju Chen,Theodoros I. Roumeliotis,Ya-Hsuan Chang,Ching-Tai Chen,Chia‐Li Han,Miao-Hsia Lin,Huei‐Wen Chen,Gee‐Chen Chang,Yih‐Leong Chang,Chen‐Tu Wu,Mong‐Wei Lin,Min-Shu Hsieh,Yutai Wang,Yet‐Ran Chen,Inge Jonassen,Fatemeh Zamanzad Ghavidel,Ze-Shiang Lin,Kuen‐Tyng Lin,Ching-Wen Chen,Pei-Yuan Sheu
出处
期刊:Cell
[Cell Press]
日期:2020-07-01
卷期号:182 (1): 226-244.e17
被引量:282
标识
DOI:10.1016/j.cell.2020.06.012
摘要
Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a deep comprehensive proteogenomic study on a prospectively collected cohort in Taiwan, representing early stage, predominantly female, non-smoking lung adenocarcinoma. Integrated genomic, proteomic, and phosphoproteomic analysis delineated the demographically distinct molecular attributes and hallmarks of tumor progression. Mutational signature analysis revealed age- and gender-related mutagenesis mechanisms, characterized by high prevalence of APOBEC mutational signature in younger females and over-representation of environmental carcinogen-like mutational signatures in older females. A proteomics-informed classification distinguished the clinical characteristics of early stage patients with EGFR mutations. Furthermore, integrated protein network analysis revealed the cellular remodeling underpinning clinical trajectories and nominated candidate biomarkers for patient stratification and therapeutic intervention. This multi-omic molecular architecture may help develop strategies for management of early stage never-smoker lung adenocarcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI